Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Washington University School of Medicine
Eli Lilly and Company
Dana-Farber Cancer Institute
Xijing Hospital
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Eli Lilly and Company
AbbVie
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
University of California, San Francisco
AstraZeneca
Eli Lilly and Company
OHSU Knight Cancer Institute
Emory University
Hoffmann-La Roche
Northwestern University
H. Lee Moffitt Cancer Center and Research Institute
Rutgers, The State University of New Jersey
Wake Forest University Health Sciences
Syros Pharmaceuticals
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Merck Sharp & Dohme LLC
Novartis
AstraZeneca
AIDS Malignancy Consortium
Gilead Sciences
Hoffmann-La Roche
University of California, San Francisco
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Celgene
Oncology Institute of Southern Switzerland
AstraZeneca
The Netherlands Cancer Institute
University of Chicago
GlaxoSmithKline
AbbVie
National Cancer Institute (NCI)
City of Hope Medical Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Nippon Kayaku Co., Ltd.
Piramal Enterprises Limited
National Cancer Institute (NCI)
Mayo Clinic